GL Pharm Tech Corp.

As of June 30, 2026, GL Pharm Tech Corp. carries a market capitalization of 64.44B, placing it among publicly traded companies globally. Its enterprise value stands at 81.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, GL Pharm Tech Corp. has 15.51M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.72, and the price-to-book ratio stands at 3.24.

As of June 30, 2026, GL Pharm Tech Corp. trades at an EV/EBITDA multiple of 60.23 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 365.12 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 81.86B versus a market cap of 64.44B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, GL Pharm Tech Corp. maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.97, indicating elevated leverage, while an interest coverage ratio of 1.68 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, GL Pharm Tech Corp. posted a negative return on equity (ROE) of -0.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.23, reflecting losses generated across the asset base. The company generates approximately 1.26B in revenue per employee across its workforce of 30.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.15 indicates how many times GL Pharm Tech Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, GL Pharm Tech Corp. recorded 63.51M in income tax expense. The company reported a pretax loss of -43.60M and -107.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, GL Pharm Tech Corp.'s stock has declined approximately 39.22% over the past 52 weeks. The 50-day moving average sits at 4,396.70, while the 200-day moving average is 4,958.45.

Over the twelve months ended June 30, 2026, GL Pharm Tech Corp. generated 38.21B in revenue and converted that into -107.11M in net income, yielding earnings per share of -6.79. EBITDA reached 1.36B, while operating income came in at 224.21M.

As of June 30, 2026, GL Pharm Tech Corp. holds 3.46B in cash and equivalents against 20.88B in total debt, resulting in a net debt position of 17.30B. Total book value stands at 19.89B, with working capital of -442.35M providing operational flexibility.

GL Pharm Tech Corp. produced -354.85M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.99B in capital expenditures, free cash flow totaled -3.35B - equivalent to -212.22 per share.

Over the twelve months ended June 30, 2026, GL Pharm Tech Corp. posted a gross margin of 40.26, reflecting its pricing power and cost economics. The operating margin of 0.59 and net profit margin of -0.28 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.22, meaning GL Pharm Tech Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

GL Pharm Tech Corp.'s most recent stock split took place on August 11, 2026 with a 5:1 split ratio.

As of June 30, 2026, GL Pharm Tech Corp. has an Altman Z-Score of 1.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.